SS-31:

Clinical Overview for Mitochondrial Health and Neuroprotection



SS-31

A mitochondria-targeted peptide (elamipretide)

Restores Mitochondrial Function.
Protects Cells. Supports Life.

ENHANCES MITOCHONDRIAL EFFICIENCY

Improves electron transport chain function

REDUCES OXIDATIVE STRESS

Decreases ROS production and lipid peroxidation

SUPPORTS NEUROPROTECTION

Preserves neuronal integrity and synaptic function

POTENTIAL BENEFITS ACROSS CONDITIONS

Neurological disorders, cardiovascular disease, sarcopenia, and aging

WELL TOLERATED

Favorable safety profile in clinical studies

Targeting the Powerhouse of the Cell to Protect What Matters Most:

ENERGY. FUNCTION. BRAIN. LIFE.

Mark L. Gordon, MD

Overview

SS-31, also known as elamipretide or Bendavia, is a synthetic tetrapeptide engineered with a singular therapeutic purpose: to protect and restore mitochondrial function at its most vulnerable point, the inner mitochondrial membrane. Chemically defined as D-Arg-Dmt-Lys-Phe-NH_2, SS-31 was designed to selectively bind cardiolipin, a phospholipid found almost exclusively within mitochondria and essential for maintaining the architecture and efficiency of the electron transport chain.

Under physiological stress, cardiolipin becomes oxidized, destabilizing electron transport complexes and accelerating the leakage of electrons that generate reactive oxygen species. This cascade of oxidative stress compromises ATP production triggers apoptotic signaling, and fuels inflammatory amplification, processes that are now recognized as central drivers of neurodegeneration, ischemic injury, and systemic organ decline. SS-31 intervenes precisely at this juncture. By binding cardiolipin and preserving its functional state, the peptide stabilizes mitochondrial respiration, reduces excess reactive oxygen species at their source, and preserves cellular energy metabolism.

Originally developed in the early 2000s as part of a new class of mitochondria-targeted therapeutics, SS-31 has since accumulated a substantial body of preclinical and early clinical evidence. Its protective effects have been demonstrated across models of traumatic brain injury, ischemic stroke, Alzheimer's disease, Parkinson's disease, and other neurodegenerative conditions in which mitochondrial dysfunction precedes neuronal loss. In these settings, SS-31 consistently improves ATP generation, limits apoptotic signaling, and attenuates neuroinflammatory cascades that propagate secondary injury.

Importantly, the therapeutic relevance of SS-31 extends well beyond the central nervous system. High-energy organs such as the heart, kidneys, skeletal muscle, and retina are similarly vulnerable to mitochondrial collapse. In cardiac ischemia-reperfusion injury, SS-31 preserves cardiomyocyte viability and contractile function. In chronic kidney disease and diabetic nephropathy, it reduces oxidative injury and fibrotic progression. In ophthalmology, SS-31 has been investigated for age-related macular degeneration, where retinal cells depend heavily on mitochondrial integrity for survival.

What distinguishes SS-31 from conventional antioxidants or receptor-based peptides is its point of intervention. Rather than attempting to neutralize oxidative damage after it occurs, SS-31 acts upstream, stabilizing mitochondrial structure and preventing excessive reactive oxygen species formation altogether. This mechanism represents a conceptual shift toward what may be considered true "***mitochondrial medicine***", therapies designed to modify disease trajectories by preserving cellular energy systems themselves.

As of 2025, elamipretide remains an investigational compound. In rare mitochondrial disorders such as Barth syndrome, open-label data demonstrating improvements in cardiac function prompted regulatory engagement, although confirmatory trials were ultimately requested by the FDA. Across clinical programs, safety has been acceptable, with adverse effects largely limited to mild injection-site reactions and transient gastrointestinal symptoms. These findings, combined with its mechanistic precision, continue to position SS-31 as one of the most compelling mitochondrial-targeted peptides in development.

Mechanism of Action



The defining feature of SS-31 (elamipretide) is its ability to bypass conventional receptor-based signaling and act directly within the mitochondrion, the organelle responsible for cellular energy production, redox balance, and apoptotic regulation. This intracellular targeting places SS-31 in a distinct therapeutic category, one that addresses disease at the level of bioenergetic failure rather than downstream biochemical consequences.

After systemic administration, SS-31 rapidly traverses cellular membranes and selectively accumulates within the inner mitochondrial membrane. Its affinity for this compartment is driven by electrostatic and structural interactions with cardiolipin, a tetra-acyl phospholipid that is uniquely enriched in mitochondria and essential for maintaining the architecture of the electron transport chain. Cardiolipin serves as a molecular scaffold that stabilizes respiratory complexes and facilitates efficient electron transfer during oxidative phosphorylation.

Under conditions of physiological stress, such as ischemia, neurodegeneration (Alzheimer's, Parkinson's. Multiple Sclerosis, ALS, CTE, TBI, PTSD), inflammation, or aging, cardiolipin becomes oxidized. This oxidation disrupts electron transport chain supercomplexes, increases electron leak, and markedly elevates the production of reactive oxygen species. The resulting oxidative stress damages mitochondrial DNA, proteins, and lipids, creating a self-perpetuating cycle of declining ATP production and escalating cellular injury. SS-31 interrupts this cycle by binding cardiolipin and preserving its reduced, functional state. In doing so, it stabilizes electron transport chain activity and restores the efficiency of oxidative phosphorylation.

Crucially, the antioxidant effects of SS-31 are indirect. Rather than scavenging free radicals after they are generated, the peptide prevents excessive reactive oxygen species formation at its primary source, the electron transport chain itself. This upstream modulation distinguishes SS-31 from traditional antioxidants, which often fail clinically because they do not address the fundamental bioenergetic dysfunction driving oxidative injury. By reducing electron leak and maintaining membrane potential, SS-31 lowers oxidative stress while preserving physiological redox signaling.

Stabilization of mitochondrial energetics also has profound implications for cell survival. Loss of mitochondrial membrane integrity is a key trigger for apoptosis, mediated through the release of cytochrome c and subsequent caspase activation. SS-31 reduces this apoptotic signaling by maintaining membrane potential and limiting cardiolipin peroxidation, thereby protecting neurons and other high-energy cells from programmed cell death during injury or chronic disease states.

Mitochondrial dysfunction is increasingly recognized as a driver of inflammation, particularly within the central nervous system. Excess reactive oxygen species and mitochondrial DNA fragments act as danger signals that activate innate immune pathways, including the NLRP3 inflammasome. By preserving mitochondrial integrity, SS-31 indirectly dampens these inflammatory triggers, leading to downstream reductions in pro-inflammatory cytokines such as interleukin-1β, interleukin-6, and tumor necrosis factor-α. This coupling of metabolic preservation and immune modulation helps explain the peptide's observed benefits in neuroinflammatory and neurodegenerative conditions.

Although initially explored in neurological disease, the same mechanistic principles apply across organ systems with high energetic demand. In cardiomyocytes, SS-31 stabilizes mitochondrial respiration during ischemia-reperfusion, improving contractile recovery. In renal tubular cells, it limits oxidative injury and fibrotic signaling. In retinal neurons, it preserves photoreceptor and ganglion cell survival in the face of age-related mitochondrial decline. Across these tissues, the unifying mechanism remains the same: cardiolipin stabilization, reduced oxidative stress, preserved ATP production, and improved cellular resilience.

In essence, SS-31 acts at one of the most fundamental levels of cellular physiology. By safeguarding mitochondrial structure and function, it exerts pleiotropic effects that span energy metabolism, apoptosis regulation, and inflammatory control. This integrated mechanism provides a coherent biological explanation for the peptide's broad preclinical efficacy and underpins its continued investigation as a disease-modifying therapy in conditions rooted in mitochondrial failure.

---END

If you would like more information on this specific peptide and 29 others, you can find it all in the Peptide for Health books. https://millenniumhealthstore.com/collections/educational-products

Thank you

Mark L. Gordon, MD